# Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas

> **NCT01188785** · PHASE1 · COMPLETED · sponsor: **Silenseed Ltd** · enrollment: 15 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** siG12D LODER

## Key facts

- **NCT ID:** NCT01188785
- **Lead sponsor:** Silenseed Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188785, "Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01188785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*